2022 Biopharma Omics Virtual Seminar - Day 2
This online event will focus on improving the collection and processing of multi-omics data during the drug discovery process to enable the development of more effective drugs. The technologies presented are LC-MS and software solutions.
Over the course of 2 days, for 2 hours each day, you will learn about new workflows from top scientists and industry innovators and get the latest news from SCIEX.
Preliminary agenda April 25, 2022
10:05 a.m. – 10:25 a.m. (CEST) Functional proteomics in discovery and translational medicine - part 1
- presented by Nikolaus Berndt
In part 1 of this 2-part session, we’ll look at SWATH-based metabolic profiling of cells and tissue samples. You will learn about the benefits of using QSM (quantitative system metabolism) technology for animal model characterization, functional classification and disease stratification.
10:25 a.m. – 10:50 a.m. (CEST) Functional proteomics in discovery and translational medicine - part 2
- presented by Jan Detmers
In part 2 of this 2-part session, we’ll look at deep metabolic profiling in oncology, immunology, neurology, metabolic disorders and toxicology. You will learn about the latest QSM case studies in preclinical science and clinical trial support.
10:50 a.m. – 11:20 a.m. (CEST) Robust and ultra-sensitive bioanalysis using the SCIEX 7500 system
- presented by Jack Steed, SCIEX
In this presentation, we will cover the analysis of glucosylsphingosine (GluSPH) and galactosylsphingosine (GalSPH) in cerebral spinal fluid, highlighting the sensitivity increase achieved with the SCIEX 7500 system when compared with the SCIEX Triple Quad 6500+ system. We’ll also see how increased sensitivity allows for a smaller volume of cerebral spinal fluid to be used for analysis, increasing the number of assays that can be performed using a single sample. Finally, we’ll discover the high levels of robustness available when using the SCIEX 7500 system over 1,500 plasma sample injections.
11:20 a.m. – 12:05 p.m. (CEST) TBD
- Presentation by Thomas Hankemeier
Title will be communicated soon
Invited speakers
Bruno Manadas, PhD (Center for Neuroscience and Cell Biology, University of Coimbra)
Bruno Manadas is a PI at CNC and established his lab as a node of the National Mass Spectrometry Network performing mainly untargeted quantitative proteomics screenings to identify disease biomarkers and elucidate biological mechanisms. He has over 100 publications with recent advances in translational approaches applied to neurodegenerative and psychiatry disorders.
Martin Giera, PhD (Leiden University Medical Center)
Martin Giera studied pharmacy in Heidelberg and Munich. He was a visiting scientist at Harvard Medical School and the Scripps Research Institute, and is currently head of the metabolomics group at the Leiden University Medical Center. Martin is involved in several multi-national consortia, is a member of several editorial boards and is chairman of the interdisciplinary committee at FWO. He has a keen interest in metabolomics technology, drug development and biochemistry, and has published more than 150 scientific publications and books.
Nikolaus Berndt, PhD (Institute of Biochemistry, Charité - Universitätsmedizin Berlin)
Nikolaus Berndt is CSO at Doppelganger and leads a systems medicine research group at Charité - Universitätsmedizin Berlin. His research team performs metabolic and biophysical analysis, and simulations in systems medicine.
Jan Detmers, PhD (Doppelganger Biosystem GmbH, Berlin)
Jan Detmers is a multi-omics scientist and VP of Precision Medicine at Doppelganger. His team supports pharmaceutical and biotech companies in translational science and clinical study bioanalysis using proteomics-based fluxomics.
Thomas Hankemeier, PhD (Leiden University)
Thomas Hankemeier has been full professor of Analytical BioSciences at the LACDR at Leiden University since 2004, where he is principal investigator for the Analytical BioSciences and Metabolomics group. His research is aimed at innovative analytical tools for metabolomics-driven systems biology in personalized health strategies.
